During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Investigators will have a choice of standard of care regimens such as: pomalidomide, bortezomib, and dexamethasone; daratumumab, pomalidomide, and dexamethasone; carfilzomib, daratumumab and ...